Genmab A/S (FRA:GE91)

Market Cap	16.82B
Revenue (ttm)	3.28B
Net Income (ttm)	1.35B
Shares Out	n/a
EPS (ttm)	21.39
PE Ratio	12.46
Forward PE	17.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	75
Open	27.40
Previous Close	27.00
Day's Range	27.40 - 28.00
52-Week Range	15.90 - 28.60
Beta	n/a
RSI	58.28
Earnings Date	Feb 5, 2026

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 2,682
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GE91

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD